Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Abstract Background Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long ter...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Respiratory Research
المؤلفون الرئيسيون:	Alberto M. Marra, Michael Halank, Nicola Benjamin, Eduardo Bossone, Antonio Cittadini, Christina A. Eichstaedt, Benjamin Egenlauf, Satenik Harutyunova, Christine Fischer, Henning Gall, Hossein Ardeschir Ghofrani, Marius M. Hoeper, Tobias J. Lange, Karen M. Olsson, Hans Klose, Ekkehard Grünig
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	BMC 2018-12-01
الموضوعات:	Pulmonary hypertension Pulmonary arterial hypertension Chronic thromboembolic pulmonary hypertension Riociguat Soluble guanylate cyclase stimulator Right atrial area
الوصول للمادة أونلاين:	http://link.springer.com/article/10.1186/s12931-018-0957-y

مواد مشابهة

Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
حسب: N. H. Kim
منشور في: (2010-03-01)

Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective
حسب: Mihalek AD, وآخرون
منشور في: (2022-10-01)

The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat
حسب: S. E. Gratsianskaya, وآخرون
منشور في: (2020-10-01)

Modern view on the place of riociguat in the treatment of pulmonary hypertension
حسب: Z S Valieva, وآخرون
منشور في: (2018-04-01)

CLINICAL CASE OF REPLACEMENT OF ENDOTHELIN RECEPTOR ANTAGONIST (BOSENTAN) BY SOLUBLE GUANYLATE CYCLASE STIMULATOR (RIOCIGUAT) IN THE PATIENT WITH PULMONARY ARTERIAL HYPERTENSION
حسب: E. A. Devetyarova, وآخرون
منشور في: (2018-06-01)

Pharmacological effects of a new soluble guanylate cyclase stimulator in experimental pulmonary arterial hypertension
حسب: V. V. Bykov, وآخرون
منشور في: (2023-04-01)

Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy
حسب: H. A. Ghofrani, وآخرون
منشور في: (2009-03-01)

Better efficacy of sequential combination with balloon pulmonary angioplasty after long‐term riociguat for patients with inoperable chronic thromboembolic pulmonary hypertension
حسب: Wei Wang, وآخرون
منشور في: (2024-07-01)

Soluble Guanylyl Cyclase Activators—Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension
حسب: Grzegorz Grześk, وآخرون
منشور في: (2023-01-01)

Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study
حسب: Humberto García Aguilar, وآخرون
منشور في: (2022-07-01)

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
حسب: Lian TY, وآخرون
منشور في: (2017-04-01)

Switching Strategy in the Management of Patients with Pulmonary Arterial Hypertension. The REPLACE Study Results
حسب: E. V. Filippov
منشور في: (2020-12-01)

Riociguat is a novel medication for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
حسب: N. A. Tsareva, وآخرون
منشور في: (2016-12-01)

Results of long-term riociguat therapy, including a switching strategy from sildenafil, in patients with pulmonary hypertension of various genesis
حسب: S. A. Musashaykhova, وآخرون
منشور في: (2023-11-01)

THE ROLE OF RIOCIGUAT IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE
حسب: O. Ya. Vasiltseva, وآخرون
منشور في: (2019-12-01)

Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study
حسب: Julia Degering, وآخرون
منشور في: (2023-01-01)

Long-term oxygen therapy in precapillary pulmonary hypertension – SOPHA study
حسب: Nicola Benjamin, وآخرون
منشور في: (2024-09-01)

Soluble Guanylate Cyclase Stimulators for Chronic Thromboembolic Pulmonary Hypertension Patients Treatment: New Data
حسب: M. A. Simakova, وآخرون
منشور في: (2020-05-01)

Meta‐Analysis of Real‐World Clinical Practice to Assess the Effectiveness of Riociguat in Treating Chronic Thromboembolic Pulmonary Hypertension
حسب: Esra Pamukçu, وآخرون
منشور في: (2025-02-01)

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide
حسب: L. T. Domingo, وآخرون
منشور في: (2022-12-01)

Advances in Balloon Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
حسب: GAO Luyang, وآخرون
منشور في: (2023-09-01)

Nitric oxide activates AMPK by modulating PDE3A in human pulmonary artery smooth muscle cells
حسب: Julie Dillard, وآخرون
منشور في: (2020-09-01)

Different Effects of Riociguat and Vericiguat on Pulmonary Vessels and Airways
حسب: Katharina Nubbemeyer, وآخرون
منشور في: (2025-04-01)

Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty – A randomized controlled study
حسب: Tatsuo Aoki, وآخرون
منشور في: (2020-08-01)

Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats
حسب: Yi Tong, وآخرون
منشور في: (2018-09-01)

Treatment Strategy Options in Inoperable Chronic Thromboembolic Pulmonary Hypertension Patients
حسب: N. V. Marukyan, وآخرون
منشور في: (2021-05-01)

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
حسب: Yu-Yang Liu, وآخرون
منشور في: (2023-01-01)

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
حسب: Yu-Yang Liu, وآخرون
منشور في: (2023-02-01)

Rehabilitation in patients with pulmonary arterial hypertension
حسب: Stephan Keusch, وآخرون
منشور في: (2017-07-01)

Association Between Copayment and Adherence to Medications for Pulmonary Arterial Hypertension
حسب: Erin M. Schikowski, وآخرون
منشور في: (2022-11-01)

Modern possibilities of echocardiographic diagnosis in pulmonary arterial hypertension
حسب: A. A. Klimenko, وآخرون
منشور في: (2025-01-01)

EFFICACY OF MULTIDISCIPLINARY MANAGEMENT OF PULMONARY HYPERTENSION
حسب: I. R. Gaisin, وآخرون
منشور في: (2017-02-01)

The impact of riociguat on clinical parameters and quality of life in patients with chronic thromboembolic pulmonary hypertension - results of a retrospective clinical registry
حسب: Pavel Jansa, وآخرون
منشور في: (2021-06-01)

Possibilities of long-term effective treatment of idiopathic pulmonary arterial hypertension by replacing sildenafil with riociguat and using sequential combination therapy: case report
حسب: S. A. Musashaykhova, وآخرون
منشور في: (2022-12-01)

Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
حسب: Bajwa EK, وآخرون
منشور في: (2024-05-01)

Predicting Response to Switching From Phosphodiesterase Type 5 Inhibitor to Riociguat in Patients With Pulmonary Arterial Hypertension: Biomarker and Responder Analysis of the RESPITE and REPLACE Studies
حسب: James R. Klinger, وآخرون
منشور في: (2025-07-01)

Recent trends in pulmonary arterial hypertension
حسب: Rajagopalan Natarajan
منشور في: (2011-01-01)

Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres
حسب: Max Wissmüller, وآخرون
منشور في: (2022-10-01)

A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?
حسب: N A Tsareva, وآخرون
منشور في: (2017-09-01)

Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
حسب: Munish Sharma, وآخرون
منشور في: (2021-04-01)